Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The effect of graded, physiologic hyperinsulinemia (+5, +15, +30, +70, +200 microU/ml) on oxidative and nonoxidative pathways of glucose and FFA metabolism was examined in nine lean non-insulin dependent diabetic patients (NIDDM) and in eight age- and weight-matched control subjects. Glucose and FFA metabolism were assessed using stepwise insulin clamp in combination with indirect calorimetry and infusion of [3H]3-glucose/[14C]palmitate. The basal rate of hepatic glucose production (HGP) was higher in NIDDM than in control subjects, and suppression of HGP by insulin was impaired at all but the highest insulin concentration. Glucose disposal was reduced in the NIDD patients at the three highest plasma insulin concentrations, and this was accounted for by defects in both glucose oxidation and nonoxidative glucose metabolism. In NIDDs, suppression of plasma FFA by insulin was impaired at all five insulin steps. This was associated with impaired suppression by insulin of plasma FFA turnover, FFA oxidation (measured by [14C]palmitate) and nonoxidative FFA disposal (an estimate of reesterification of FFA). FFA oxidation and net lipid oxidation (measured by indirect calorimetry) correlated positively with the rate of HGP in the basal state and during the insulin clamp. In conclusion, our findings demonstrate that insulin resistance is a general characteristic of glucose and FFA metabolism in NIDDM, and involves both oxidative and nonoxidative pathways. The data also demonstrate that FFA/lipid and glucose metabolism are interrelated in NIDDM, and suggest that an increased rate of FFA/lipid oxidation may contribute to the impaired suppression of HGP and diminished stimulation of glucose oxidation by insulin in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Plasma insulin concentrations such as those observed during the present insulin/glucose or glucose infusion studies, are known to completely suppress hepatic glucose production (27); thus, under these conditions, total glucose uptake is equal to exogenous glucose infusion.”
From Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans (1993) · cites this paper as [27]
In the citing paper
“Notably, insulin resistance is also associated with a decreased ability to suppress lipolysis in adipose tissue and altered fatty acid oxidation.50,51”
From The effects of sleep disruption on metabolism, hunger, and satiety, and the influence of psychosocial stress and exercise: A narrative review (2024) · cites this paper as [51]
In the citing paper
“In lean healthy individuals insulin stimulates glucose uptake into skeletal muscle in a dose-dependent manner, with a half-maximal effect (EC50) at a plasma insulin concentration ~60 μU/mL [21].”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [21]
In the citing paper
“Using the gold standard euglycemic hyperinsulinemic clamp technique to quantify insulin-stimulated glucose uptake, they demonstrated that both lean and obese T2DM subjects have marked decrease (>50%) in whole body glucose disposal during the insulin clamp.”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [21]
In the citing paper
“During the postabsorptive state, the plasma insulin concentration is low. Since the plasma insulin concentration is the principal factor that restrains lipolysis in adipocytes [21] and stimulates glucose uptake in skeletal muscle [21], during the fasting state, muscle glucose uptake is low and the plasma FFA concentration is elevated.”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [21]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationRandle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 2×
“More than 20 years ago Randle and co-workers introduced the concept of substrate competition, whereby enhanced availability and oxidation of FFA leads to an impairment in glucose oxidation (17).”
BackgroundImmunoassay of insulin with insulin-antibody precipitate
HALES, C., & RANDLE, P. (1963) · Biochemical Journal · doi:10.1042/bj0880137 · Cited by 2,638
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580
Self-citationRegulation of hepatic fatty acid oxidation and ketone body production
McGarry, J. D., & Foster, D. W. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002143 · Cited by 1,460 · cited 1×
“Since CPT I is inhibited by both insulin and malonyl-CoA, which is generated by condensation of acetyl-CoA (56), the insulin-mediated decline in FFA oxidation could have been due to a direct effect of the hormone on CPT I.”
BackgroundRelationship Between Carbohydrate and Lipid Metabolism and the Energy Balance of Heart Muscle
Neely, J. R., & Morgan, H. E. (1974) · Annual Review of Physiology · doi:10.1146/annurev.ph.36.030174.002213 · Cited by 1,261
DeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167 · cited 2×
“in insulin-mediated glucose metabolism affects both hepatic and peripheral tissues, primarily muscle (1-6).”
BackgroundSelf-citationEffect of fatty acids on glucose production and utilization in man.
Ferrannini, E., Barrett, E. J., Bevilacqua, S., & DeFronzo, R. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111133 · Cited by 1,050
Self-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Kolterman, O. G., Gray, R. S., Griffin, J., Burstein, P., Insel, J., Scarlett, J. A., & Olefsky, J. M. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110350 · Cited by 629
Cited by
Items 101–200 of 812
Central adiposity and its metabolic correlates in obese adolescent girls
Caprio, S., Hyman, L. D., Limb, C., McCarthy, S., Lange, R., Sherwin, R. S., Shulman, G., & Tamborlane, W. V. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.1.e118 · Cited by 191
Hwang, J.-H., Stein, D. T., Barzilai, N., Cui, M.-H., Tonelli, J., Kishore, P., & Hawkins, M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00590.2006 · Cited by 188
“Indeed, T2DM is associated with defects in the ability of insulin both to stimulate skeletal muscle glucose uptake (“peripheral” insulin resistance) and to suppress endogenous glucose production (“hepatic” insulin resistance) (12).”
Backgroundthe Metascreen Writing Committee (2006) · Diabetes Care · doi:10.2337/dc06-0942 · Cited by 188
“Insulin resistance is a main feature of obesity and type 2 diabetes (1,2) and can be detected in hypertension and atherogenic dyslipidemia (high triglycerides and/or low HDL cholesterol) (3–6).”
BackgroundDapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Merovci, A., Mari, A., Solis, C., Xiong, J., Daniele, G., Chavez-Velazquez, A., Tripathy, D., Urban McCarthy, S., Abdul-Ghani, M., & DeFronzo, R. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3472 · Cited by 186
“For example, insulin is a powerful inhibitor of lipolysis and markedly lowers the plasma free fatty acid (FFA) concentration (12), which could lead to improved -cell function (13).”
BackgroundSelf-citationDIABETIC KETOACIDOSIS AND HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC SYNDROME
Delaney, M. F., Zisman, A., & Kettyle, W. M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70159-6 · Cited by 187
Splanchnic regulation of glucose production
Wahren, J., & Ekberg, K. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093806 · Cited by 185
Bajaj, M., Suraamornkul, S., Romanelli, A., Cline, G. W., Mandarino, L. J., Shulman, G. I., & DeFronzo, R. A. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3148 · Cited by 181
Self-citationGroop, L. C., Kankuri, M., Schalin-Jantti, C., Ekstrand, A., Nikula-Ijas, P., Widen, E., Kuismanen, E., Eriksson, J., Franssila-Kallunki, A., Saloranta, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301073280102 · Cited by 181
Self-citationRole of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man.
Groop, L. C., Bonadonna, R. C., Shank, M., Petrides, A. S., & DeFronzo, R. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115005 · Cited by 181
Self-citationThe importance of free fatty acids in the development of Type 2 diabetes
Wilding, J. P. H. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02186.x · Cited by 178
Carbohydrate fermentation decreases hepatic glucose output in healthy subjects
Thorburn, A., Muir, J., & Proietto, J. (1993) · Metabolism · doi:10.1016/0026-0495(93)90249-n · Cited by 178
The Emerging Functions of UCP2 in Health, Disease, and Therapeutics
Mattiasson, G., & Sullivan, P. G. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1 · Cited by 177
“atherosclerotic plaque build up, myocardial infarction, heart”
Shiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., Yamaguchi, S., Ogasawara, N., Katoh, M., Itoh, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19658-7 · Cited by 175
Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus
Foley, J. E. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.773 · Cited by 174
“Effects of fatty acids on glucose metabolism in muscle The muscle is the main site of insulinmediated glucose disposal (28).”
BackgroundInfluentialOral insulin delivery: existing barriers and current counter-strategies
Gedawy, A., Martinez, J., Al-Salami, H., & Dass, C. R. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12852 · Cited by 172
Lipolysis and the integrated physiology of lipid energy metabolism
Wang, S., Soni, K. G., Semache, M., Casavant, S., Fortier, M., Pan, L., & Mitchell, G. A. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.06.012 · Cited by 171
Insulin Resistance of Glycogen Synthase Mediated byO-Linked N-Acetylglucosamine
Parker, G. J., Lund, K. C., Taylor, R. P., & McClain, D. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207787200 · Cited by 170
Del Prato, S., Bonadonna, R. C., Bonora, E., Gulli, G., Solini, A., Shank, M., & DeFronzo, R. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116226 · Cited by 170
“In NIDDM, nonoxidative glucose metabolism is markedly reduced compared to normal individuals (11, 14).”
BackgroundResultSelf-citationPathophysiology of Non Alcoholic Fatty Liver Disease
Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Svegliati-Baroni, G., Valenti, L., & Bonino, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122082 · Cited by 170
“In the presence of adipose tissue insulin resistance, FFA levels are high, despite high levels of circulating insulin, because of the resistance to the anti-lipolytic action of this hormone [1,2].”
BackgroundInsulin action in adipocytes, adipose remodeling, and systemic effects
Santoro, A., McGraw, T. E., & Kahn, B. B. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.019 · Cited by 168
“Indeed, FFA levels are not necessarily elevated in humans with T2D (Fraze et al., 1985; Groop et al., 1989; Reaven et al., 1988; Swislocki et al., 1987).”
BackgroundTotal-body and myocardial substrate oxidation in congestive heart failure
Paolisso, G., Gambardella, A., Galzerano, D., D'Amore, A., Rubino, P., Verza, M., Teasuro, P., Varricchio, M., & D'Onofrio, F. (1994) · Metabolism · doi:10.1016/0026-0495(94)90241-0 · Cited by 166
Bradley, R. L., Fisher, F. M., & Maratos‐Flier, E. (2008) · Obesity · doi:10.1038/oby.2008.39 · Cited by 160
Mechanisms modifying glucose oxidation in diabetes mellitus
Randle, P. J., Priestman, D. A., Mistry, S., & Halsall, A. (1994) · Diabetologia · doi:10.1007/bf00400839 · Cited by 160
Insulin Resistance Syndrome in Women with Prior History of Gestational Diabetes Mellitus
Verma, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3227 · Cited by 161
Bajaj, M., Suraamornkul, S., Hardies, L. J., Pratipanawatr, T., & DeFronzo, R. A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802625 · Cited by 159
Self-citationSevastianova, K., Kotronen, A., Gastaldelli, A., Perttilä, J., Hakkarainen, A., Lundbom, J., Suojanen, L., Orho-Melander, M., Lundbom, N., Ferrannini, E., et al. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.012369 · Cited by 160
Self-citationMartinez-Outschoorn, U. E., Pestell, R. G., Howell, A., Tykocinski, M. L., Nagajyothi, F., Machado, F. S., Tanowitz, H. B., Sotgia, F., & Lisanti, M. P. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18487 · Cited by 157
Cellular and Molecular Mechanisms of Non-Insulin Dependent Diabetes Mellitus
Kruszynska, Y. T., & Olefsky, J. M. (1996) · Journal of Investigative Medicine · doi:10.1177/108155899604400806 · Cited by 176
Subchronic sleep restriction causes tissue-specific insulin resistance
Rao, M. N., Neylan, T. C., Grunfeld, C., Mulligan, K., Schambelan, M., & Schwarz, J.-M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3911 · Cited by 156
“Age, y, mean SD 27 5 Male sex, n (%) 8 (57) Race/ethnicity, n (%) Caucasian 5 (36) Hispanic 4 (29) Asian 4 (29) African-American 1 (7) Fasting glucose, mg/dL, mean SD 81 7 HOMA-IR, mean SD 2.”
BackgroundInsulin Resistance and Mitochondrial Dysfunction
González-Franquesa, A., & Patti, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_25 · Cited by 176
Kowalski, G. M., & Bruce, C. R. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00165.2014 · Cited by 154
“However, muscle has a greater capacity to take up glucose at progressively higher insulin doses, such that muscle glucose uptake can continue to increase at insulin concentrations where EGP is already maximally suppressed (7, 12, 24, 79, 147, 151, 153).”
BackgroundInfluentialMostad, I. L., Bjerve, K. S., Bjorgaas, M. R., Lydersen, S., & Grill, V. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.3.540 · Cited by 152
“There were no differences in the concentrations of FFAs between samples with and without paraoxon .”
BackgroundFat metabolism in human obesity
Campbell, P. J., Carlson, M. G., & Nurjhan, N. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.4.e600 · Cited by 154
Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease
Henderson, G. C. (2021) · Nutrients · doi:10.3390/nu13082590 · Cited by 152
“Indeed suppression of plasma FFA concentration by insulin is blunted in T2D [45], as well as in other instances of IR such as sleep deprivation [110] and following cigarette smoking [58,113]; furthermore, weight loss via gastric bypass surgery [94] and treatment of sleep apnea [55] each enhance the ability to suppress…”
BackgroundLupi, R., Del Guerra, S., Marselli, L., Bugliani, M., Boggi, U., Mosca, F., Marchetti, P., & Del Prato, S. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00561.2002 · Cited by 152
Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis.
Petrides, A. S., Groop, L. C., Riely, C. A., & DeFronzo, R. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115340 · Cited by 151
Self-citationTransmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes.
Bonadonna, R. C., Del Prato, S., Saccomani, M. P., Bonora, E., Gulli, G., Ferrannini, E., Bier, D., Cobelli, C., & DeFronzo, R. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116592 · Cited by 149
Self-citationMitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus
Abdul-Ghani, M. A., & DeFronzo, R. A. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0030-1 · Cited by 146
Self-citationPathophysiology of prediabetes
Abdul-Ghani, M. A., & DeFronzo, R. A. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0032-7 · Cited by 178
“Insulin is a potent inhibitor of lipolysis [ 27 ].”
BackgroundSelf-citationMetabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
Lomonaco, R., Bril, F., Portillo-Sanchez, P., Ortiz-Lopez, C., Orsak, B., Biernacki, D., Lo, M., Suman, A., Weber, M. H., & Cusi, K. (2016) · Diabetes Care · doi:10.2337/dc15-1876 · Cited by 146
“FPI level and inhibition of plasma EGP and FFA in healthy subjects, respectively (29).”
Rabasa-Lhoret, R., Bastard, J.-P., Jan, V., Ducluzeau, P.-H., Andreelli, F., Guebre, F., Bruzeau, J., Louche-Pellissier, C., MaÎtrepierre, C., Peyrat, J., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030316 · Cited by 149
Essential hypertension, metabolic disorders, and insulin resistance
Ferrannini, E., & Natali, A. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90433-i · Cited by 163
Self-citationTumor Necrosis Factor α Stimulates Lipolysis in Adipocytes by Decreasing Gi Protein Concentrations
Gasic, S., Tian, B., & Green, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6770 · Cited by 143
Analysis of techniques to obtain plasma for measurement of levels of free fatty acids
Zambon, A., Hashimoto, S., & Brunzell, J. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39687-5 · Cited by 143
Bonadonna, R. C., Heise, T., Arbet-Engels, C., Kapitza, C., Avogaro, A., Grimsby, J., Zhi, J., Grippo, J. F., & Balena, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1041 · Cited by 141
“Variations of the order of magnitude we observed at the higher piragliatin dose should be quite effective in restraining hepatic glucose production (19, 20).”
BackgroundMethodInfluentialSelf-citationAbdul-Ghani, M. A., Muller, F. L., Liu, Y., Chavez, A. O., Balas, B., Zuo, P., Chang, Z., Tripathy, D., Jani, R., Molina-Carrion, M., et al. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90287.2008 · Cited by 140
“The plasma FFA concentration strongly correlates with whole body insulin sensitivity, measured with the insulin clamp technique (18, 19), and experimental elevation of plasma FFA concentration in insulin-sensitive subjects causes a dose-dependent decrease in whole body insulin sensitivity, associated with impaired ins…”
Self-citationPPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
Martin, G., Schoonjans, K., Staels, B., & Auwerx, J. H. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00315-8 · Cited by 161
“This change is usually associated with an increased insulin sensitivity of the adipocyte and will hence, also result in a decrease in HSL activity [59].”
BackgroundGroop, L., Wid�n, E., & Ferrannini, E. (1993) · Diabetologia · doi:10.1007/bf00400814 · Cited by 162
“In contrast, suppression of HGP is seen at much lower insulin concentrations (Fig. 1) [ 24 ].”
BackgroundSelf-citationHepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“Another important result of the study by Groop and colleagues is that in the presence of Hep-IR, as in obesity and T2D, the curve is shifted to the right, indicating that higher insulin concentrations are needed to suppress EGP 5,15 .”
Alnahdi, A., John, A., & Raza, H. (2019) · Nutrients · doi:10.3390/nu11091979 · Cited by 134
Recent Progress on Branched-Chain Amino Acids in Obesity, Diabetes, and Beyond
Siddik, M. A. B., & Shin, A. C. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.234 · Cited by 151
Insulin regulation of renal glucose metabolism in conscious dogs.
Cersosimo, E., Judd, R. L., & Miles, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117270 · Cited by 133
Groop, L. C., Bonadonna, R. C., Simonson, D. C., Petrides, A. S., Shank, M., & DeFronzo, R. A. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.263.1.e79 · Cited by 130
Self-citationMetabolic basis of obesity and noninsulin‐dependent diabetes mellitus
Golay, A., Jp, F., Jéquier, E., DeFronzo, R. A., & Ferrannini, E. (1988) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610040803 · Cited by 146
Self-citationBhansali, A., Upreti, V., Khandelwal, N., Marwaha, N., Gupta, V., Sachdeva, N., Sharma, R. R., Saluja, K., Dutta, P., Walia, R., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0164 · Cited by 129
“Insulin therapy is not physiological as there is no hepatic “fi rst-pass” metabolism of insulin [7], which is required to knock down hepatic glucose output.”
Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM
Utriainen, T., Takala, T., Luotolahti, M., Rönnemaa, T., Laine, H. K., Ruotsalainen, U., Haaparanta‐Solin, M., Nuutila, P., & Yki‐Järvinen, H. (1998) · Diabetologia · doi:10.1007/s001250050946 · Cited by 140
“Since lipolysis is exquisitely sensitive to insulin [29] and since the antilipolytic effect of insulin may be altered by NIDDM or obesity [30], the present data do not exclude the existence of myocardial insulin resistance under conditions where myocardial glucose uptake is dependent upon plasma NEFA availability [12,…”
BackgroundLaws, A., Hoen, H. M., Selby, J. V., Saad, M. F., Haffner, S. M., & Howard, B. V. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.1.64 · Cited by 128
Exercise in the Management of Non???Insulin-Dependent Diabetes Mellitus
Wallberg‐Henriksson, H., Rincón, J., & Zierath, J. R. (1998) · Sports Medicine · doi:10.2165/00007256-199825010-00003 · Cited by 158
“[20,23] Thus, in vivo methods have provided indirect evidence to suggest that the reduced rate of nonoxidative glucose metabolism observed in patients with NIDDM may result from a defect at the level of glucose transport, glucose phosphorylation or glycogen synthase.”
BackgroundBhansali, S., Dutta, P., Kumar, V., Yadav, M. K., Jain, A., Mudaliar, S., Bhansali, S., Sharma, R. R., Jha, V., Marwaha, N., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0275 · Cited by 126
“Therefore, targeting b -cells through pancreatic/islet transplantation and novel b -cell regenerative therapies such as stem cells seems to be a pragmatic approach [6,7].”
Mashili, F., Chibalin, A. V., Krook, A., & Zierath, J. R. (2013) · Diabetes · doi:10.2337/db12-0337 · Cited by 125
“Moreover, insulinmediated suppression of plasma FFA is impaired in T2D, coupled with impairments in plasma FFA turnover, FFA oxidation, and nonoxidative FFA disposal (20).”
BackgroundIron Metabolism Is Associated With Adipocyte Insulin Resistance and Plasma Adiponectin
Wlazlo, N., van Greevenbroek, M. M. J., Ferreira, I., Jansen, E. H. J. M., Feskens, E. J. M., van der Kallen, C. J. H., Schalkwijk, C. G., Bravenboer, B., & Stehouwer, C. D. A. (2013) · Diabetes Care · doi:10.2337/dc12-0505 · Cited by 125
Anderwald, C., Gastaldelli, A., Tura, A., Krebs, M., Promintzer-Schifferl, M., Kautzky-Willer, A., Stadler, M., DeFronzo, R. A., Pacini, G., & Bischof, M. G. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1398 · Cited by 124
“with insulin concentrations in logarithmic manner (21).”
BackgroundSelf-citationSystemic and regional free fatty acid metabolism in type 2 diabetes
Basu, A., Basu, R., Shah, P., Vella, A., Rizza, R. A., & Jensen, M. D. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.6.e1000 · Cited by 123
“Euglycemic stepwise insulin clamp studies have shown reduced insulin suppression of lipolysis in nonobese subjects with type 2 diabetes (12).”
BackgroundFerrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Pettiti, M., Natali, A., Mari, A., & DeFronzo, R. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1169-6 · Cited by 133
Self-citationEriksson, J., Koranyi, L., Bourey, R., Schalin-J�ntti, C., Wid�n, E., Mueckler, M., Permutt, A. M., & Groop, L. C. (1992) · Diabetologia · doi:10.1007/bf00402546 · Cited by 122
“Insulin resistance is a characteristic feature of Type 2 (non-insulin-dependent) diabetes mellitus involving both the oxidative and non-oxidative pathway of glucose metabolism [1, 2].”
BackgroundBhansali, A., Asokumar, P., Walia, R., Bhansali, S., Gupta, V., Jain, A., Sachdeva, N., Sharma, R. R., Marwaha, N., & Khandelwal, N. (2014) · Cell Transplantation · doi:10.3727/096368913x665576 · Cited by 121
Engineered skeletal muscles for disease modeling and drug discovery
Wang, J., Khodabukus, A., Rao, L., Vandusen, K., Abutaleb, N., & Bursac, N. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119416 · Cited by 115
Carlsson, M., Wessman, Y., Almgren, P., & Groop, L. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1588 · Cited by 95
Self-citationThe Mystery of Diabetes and Atherosclerosis: Time for a New Plot
Semenkovich, C. F., & Heinecke, J. W. (1997) · Diabetes · doi:10.2337/diab.46.3.327 · Cited by 137
“There is no direct evidence that increased FAS expression at this site increases portal free fatty acids, but such a mechanism could help explain insulin resistance associated with abdominal obesity (55).”
BackgroundGastaldelli, A., Miyazaki, Y., Pettiti, M., Buzzigoli, E., Mahankali, S., Ferrannini, E., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031941 · Cited by 117
Self-citationVariants in the Calpain-10 Gene Predispose to Insulin Resistance and Elevated Free Fatty Acid Levels
Orho‐Melander, M., Klannemark, M., Svensson, M., Ridderstråle, M., Lindgren, C. M., & Groop, L. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2658 · Cited by 127
“Although lipolysis is highly sensitive to the suppressive effect of insulin, patients with type 2 diabetes maintain slightly elevated rates of FFA turnover throughout the day (15).”
Self-citationCOVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes
Bigdelou, B., Sepand, M. R., Najafikhoshnoo, S., Negrete, J. A. T., Sharaf, M., Ho, J. Q., Sullivan, I., Chauhan, P. S., Etter, M. M., Shekarian, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890517 · Cited by 143
“High levels of inflammatory cells can affect the liver and skeletal muscle functions, both of which respond to insulin and absorb most of the body’s insulin-mediated glucose (54).”
BackgroundSystemic and Forearm Triglyceride Metabolism
Miles, J. M., Park, Y. S., Walewicz, D., Russell-Lopez, C., Windsor, S., Isley, W. L., Coppack, S. W., & Harris, W. S. (2004) · Diabetes · doi:10.2337/diabetes.53.3.521 · Cited by 114
“4 mol kg 1 min 1 in obese nondiabetic (30) and type 2 diabetic (31,32) individuals, FFA appearance is also increased in the postabsorptive (18,33,34) and postprandial (6,18) states in these individuals.”
BackgroundInsulin translates unfavourable lifestyle into obesity
Kolb, H., Stumvoll, M., Kramer, W., Kempf, K., & Martin, S. (2018) · BMC Medicine · doi:10.1186/s12916-018-1225-1 · Cited by 113
Demonstration, of Insulin Resistance in Coronary Artery Disease Documented With Angiography
Shinozaki, K., Suzuki, M., Ikebuchi, M., Hara, Y., & Harano, Y. (1996) · Diabetes Care · doi:10.2337/diacare.19.1.1 · Cited by 112
Decreased expression of hepatic glucokinase in type 2 diabetes
Haeusler, R. A., Camastra, S., Astiarraga, B., Nannipieri, M., Anselmino, M., & Ferrannini, E. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.12.007 · Cited by 111
“A potential explanation is that DNL contributes to only a portion of circulating triglyceride levels [26e28], the major fraction originating from reesterification of free fatty acids; the latter substrate circulates in increased amounts in type 2 diabetic patients due to insulin resistance of lipolysis [29,30].”
BackgroundSelf-citationDose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach
Natali, A., Gastaldelli, A., Camastra, S., Sironi, A. M., Toschi, E., Masoni, A., Ferrannini, E., & Mari, A. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.5.e794 · Cited by 111
“Seven adult male subjects, either healthy lean volunteers (1-4) or obese nondiabetic patients attending our metabolism clinic (5-7), were recruited (Table 1).”
BackgroundSelf-citationBajaj, M., Suraamornkul, S., Kashyap, S., Cusi, K., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0224 · Cited by 109
Self-citationInsulin: in search of a syndrome
Ferrannini, E., & Balkau, B. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00794.x · Cited by 110
Self-citationSaloranta, C., Franssila-Kallunki, A., Ekstrand, A., Taskinen, M., & Groop, L. (1991) · Diabetologia · doi:10.1007/bf00403179 · Cited by 109
“The specific activity of plasma [1JeC]NEFA was measured as previously described [2, 24].”
BackgroundMethodResultInfluentialSelf-citationKim, J. Y., Bacha, F. F., Tfayli, H. M., Michaliszyn, S. F., Yousuf, S., & Arslanian, S. A. (2018) · Diabetes Care · doi:10.2337/dc18-1178 · Cited by 119
“Therefore, a surrogate index of adipose tissue insulin resistance (Adipose-IR), calculated as the product of fasting insulin and fasting FFA concentrations (3), has been used in adults to examine”
BackgroundMethodThe Physiological Rationale for Oral Insulin Administration
Arbit, E. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/1520915041705929 · Cited by 108
Wouters, E. F. M., Bredenbröker, D., Teichmann, P., Brose, M., Rabe, K. F., Fabbri, L. M., & Göke, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2886 · Cited by 107
“Insulin normally restrains the release of FFA from the adipocyte and skeletal muscle tissue by inhibiting hormonesensitive lipase, but this ability to lower plasma FFA concentrations is reduced in DM2 (14).”
BackgroundCarcinoembryonic Antigen-Related Cell Adhesion Molecule 1
DeAngelis, A. M., Heinrich, G., Dai, T., Bowman, T. A., Patel, P. R., Lee, S. J., Hong, E., Jung, D. Y., Aßmann, A., Kulkarni, R. N., et al. (2008) · Diabetes · doi:10.2337/db08-0379 · Cited by 123
Lipid Levels in Former Gestational Diabetic Mothers
Meyers-Seifer, C. H., & Vohr, B. R. (1996) · Diabetes Care · doi:10.2337/diacare.19.12.1351 · Cited by 106
“Metabolic studies have documented insulin resistance in association with obesity, hypertension, dyslipidemia, and NIDDM (3-7).”
BackgroundAcute and chronic effects of hyperglycaemia on glucose metabolism
Yki-J�rvinen, H. (1990) · Diabetologia · doi:10.1007/bf00400200 · Cited by 114
“However, if the rate of glucose disposal is determined in Type 1 [13] or Type 2 [34] diabetic patients at glucose concentrations characterizing these patients during their everyday life, glucose utilization is normal.”
BackgroundPaolisso, G. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.6.1510 · Cited by 105
Alibegovic, A. C., Højbjerre, L., Sonne, M. P., van Hall, G., Stallknecht, B., Dela, F., & Vaag, A. (2009) · Diabetes · doi:10.2337/db09-0369 · Cited by 103
Nocturnal and Postprandial Free Fatty Acid Kinetics in Normal and Type 2 Diabetic Subjects
Miles, J. M., Wooldridge, D., Grellner, W. J., Windsor, S., Isley, W. L., Klein, S., & Harris, W. S. (2003) · Diabetes · doi:10.2337/diabetes.52.3.675 · Cited by 103
“FFA tracer studies in patients with type 2 diabetes have generally been performed under postabsorptive conditions (4,5,7) or during a hyperinsulinemic-euglycemic clamp (1,2); little information is available regarding nocturnal and postprandial FFA metabolism.”
BackgroundInfluentialThe Influence of a Low-Fat Diet on Incidence and Severity of Migraine Headaches
Bic, Z., Blix, G., Hopp, H. P., Leslie, F. M., & Schell, M. J. (1999) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/jwh.1.1999.8.623 · Cited by 103
Potential new treatments for type 2 diabetes
Bailey, C. J. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01506-6 · Cited by 124
Ectopic fat accumulation: an important cause of insulin resistance in humans.
Yki‐Järvinen, H. (2002) · Europe PMC (PubMed Central) · Cited by 120
YKI-JÄRVINEN, H., PUHAKAINEN, I., & KOIVISTO, V. A. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-6-1268 · Cited by 102
Adipose tissue fatty acid metabolism in insulin-resistant men
Bickerton, A. S. T., Roberts, R., Fielding, B. A., Tornqvist, H. E., Blaak, E. E., Wagenmakers, A. J. M., Gilbert, M., Humphreys, S. M., Karpe, F., & Frayn, K. N. (2008) · Diabetologia · doi:10.1007/s00125-008-1040-x · Cited by 109
“Defects in insulin-mediated suppression of NEFA concentrations have been shown in obesity [10], in impaired glucose tolerance [11] and in patients with type 2 diabetes [ 12 ].”
BackgroundMultiorgan insulin sensitivity in lean and obese subjects
Conte, C., Fabbrini, E., Kars, M., Mittendorfer, B., Patterson, B. W., & Klein, S. (2012) · Diabetes Care · doi:10.2337/dc11-1951 · Cited by 99
“These three different insulin infusion rates allowed assessments of adipose tissue and liver insulin sensitivities (low-dose and medium-dose insulin infusion rates during stage 1 to suppress adipose tissue lipolysis and hepatic glucose production submaximally) and skeletal muscle insulin sensitivity (high-dose insulin…”
BackgroundSantoro, D., Natali, A., Palombo, C., Brandi, L. S., Piatti, M. L., Ghione, S., & Ferrannini, E. (1992) · Hypertension · doi:10.1161/01.hyp.20.2.181 · Cited by 100
Self-citationBasu, R., Basu, A., Johnson, C. M., Schwenk, W. F., & Rizza, R. A. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2042 · Cited by 97
Aitman, T. J., Godsland, I. F., Farren, B., Crook, D., Wong, H. J., & Scott, J. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.4.748 · Cited by 97
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 95
Sidossis, L. S., Mittendorfer, B., Walser, E., Chinkes, D., & Wolfe, R. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.5.e798 · Cited by 96
Metadata
- Authors
- Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A.
- Affiliations
- University of Helsinki (FI)
- Venue
- Journal of Clinical Investigation
- Published
- 1989-07-01
- Volume
- 84
- Issue
- 1
- Pages
- 205-213
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC303971
- OpenAlex
- W1981456793
- Cited by
- 812
- References
- 61
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 28 · 2023: 15 · 2022: 27 · 2021: 30 · 2020: 19 · 2019: 17 · 2018: 25 · 2017: 32 · 2016: 26 · 2015: 22 · 2014: 22 · 2013: 26 · 2012: 26
- FWCI
- 16.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- National Institutes of Health (AM 24 092)
- Fogarty International Center (F05-TWO-3451)
- National Center for Research Resources (RR 125)
- Ministero dell'Istruzione e del Merito
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- type 2 diabetes, insulin resistance, glucose metabolism, free fatty acid metabolism, hepatic glucose production, glucose oxidation, nonoxidative glucose metabolism, fatty acid oxidation, fatty acid re-esterification, hyperinsulinemia, insulin clamp, lipid oxidation
- MeSH terms
- Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Female, Glucose, Humans, Insulin, Insulin Resistance, Liver, Male, Middle Aged, Oxidation-Reduction, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.